Brad KnottSell
Oramed Pharmaceuticals Inc. - Common Stock · Transaction Jan 10, 2025 · Filed Feb 25, 2025 · $15,001 to $50,000
NASDAQ NMS - GLOBAL MARKET · ORMP
+0.22% · +$0.0100 · Vol 178.3K
After hours · updated 16:01:48 ET
Oramed Pharmaceuticals Inc
Pharmaceuticals
$4.49
Follow $ORMP
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ORMP by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredFri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET · ORMP
Methodologysnapshot unavailable for ORMP. Cause unavailable.
Earnings absence reason unknown
ORMP
Oramed Pharmaceuticals Inc
Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
37/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Fri Oct 2 · session closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ORMP moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Oramed Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2004
Employees
13
Country
US
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$4.53
Day high
$4.57
Day low
$4.39
Previous close
$4.48
52W high
$5.34
-15.92% from high
52W low
$2.19
73% of range
Market cap
$186.4M
P/E
1.45×
EPS
$3.09
Beta
0.58
Shares out
41.6M
Volume
178.3K
0.84× rel vol
Avg volume
211.3K
VWAP
$4.45
Price history computed in-house
1W
-5.07%
1M
-11.44%
3M
-2.39%
1Y
+78.62%
YTD
+57.54%
SMA 50 $4.63 · below
SMA 200 $3.92 · above
52W position 73%
ORMP overview
Related filings and maps
Public disclosures
Congress activity in ORMP
Official filing ↗
Oramed Pharmaceuticals Inc. · Transaction Jan 14, 2022 · Filed Jan 14, 2022 · $1,001 to $15,000
Oramed Pharmaceuticals Inc. · Transaction Oct 1, 2021 · Filed Nov 3, 2021 · $1,001 to $15,000
Oramed Pharmaceuticals Inc. · Transaction Apr 23, 2021 · Filed May 24, 2021 · $1,001 to $15,000
Federal contracts
ORMP contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ORMP in this window.
Lobbying spend
ORMP lobbying filings, year to date.
Registered lobbying filings matched to Oramed Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ORMP in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ORMP.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.